91
Views
1
CrossRef citations to date
0
Altmetric
Articles

Tumoral Overexpression of Hepcidin is Associated with Poor Prognosis of Patients with Clear Cell Renal Cell Carcinoma

, , &
Pages 84-92 | Received 08 Nov 2021, Accepted 03 Oct 2022, Published online: 20 Oct 2022

References

  • Padala SA, Barsouk A, Thandra KC, Saginala K, Mohammed A, Vakiti A, et al. Epidemiology of Renal Cell Carcinoma. World J Oncol. 2020;11(3):79–87. doi:10.14740/wjon1279.
  • Clark DJ, Dhanasekaran SM, Petralia F, Pan J, Song X, Hu Y, Clinical Proteomic Tumor Analysis Consortium, et al. Integrated proteogenomic characterization of clear cell renal cell carcinoma. Cell. 2020;180(1):207. doi:10.1016/j.cell.2019.12.026.
  • Padala SA, Kallam A. 2021. Clear Cell Renal Carcinoma StatPearls. Treasure Island (FL): StatPearls Publishing; Copyright © 2021, StatPearls Publishing LLC.
  • Atkins MB, Tannir NM. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. Cancer Treat Rev. 2018;70:127–137. doi:10.1016/j.ctrv.2018.07.009.
  • Torti SV, Manz DH, Paul BT, Blanchette-Farra N, Torti FM. Iron and Cancer. Annu Rev Nutr. 2018;38:97–125. doi:10.1146/annurev-nutr-082117-051732.
  • Greene CJ, Attwood K, Sharma NJ, Gross KW, Smith GJ, Xu B, Kauffman EC. Transferrin receptor 1 upregulation in primary tumor and downregulation in benign kidney is associated with progression and mortality in renal cell carcinoma patients. Oncotarget. 2017;8(63):107052–107075. doi:10.18632/oncotarget.22323.
  • Iqbal M, Okazaki Y, Okada S. Curcumin attenuates oxidative damage in animals treated with a renal carcinogen, ferric nitrilotriacetate (Fe-NTA): implications for cancer prevention. Mol Cell Biochem. 2009;324(1-2):157–164. doi:10.1007/s11010-008-9994-z.
  • Li GH, Akatsuka S, Chew SH, Jiang L, Nishiyama T, Sakamoto A, et al. Fenton reaction-induced renal carcinogenesis in Mutyh-deficient mice exhibits less chromosomal aberrations than the rat model. Pathol Int. 2017;67(11):564–574. doi:10.1111/pin.12598.
  • Ricchi P, Ammirabile M, Spasiano A, Costantini S, Di Matola T, Cartenì G, et al. Renal cell carcinoma in adult patients with thalassaemia major: a description of three cases. Br J Haematol. 2014;165(6):887–888. doi:10.1111/bjh.12809.
  • Vargas-Olvera CY, Sánchez-González DJ, Solano JD, Aguilar-Alonso FA, Montalvo-Muñoz F, Martínez-Martínez CM, et al. Characterization of N-diethylnitrosamine-initiated and ferric nitrilotriacetate-promoted renal cell carcinoma experimental model and effect of a tamarind seed extract against acute nephrotoxicity and carcinogenesis. Mol Cell Biochem. 2012;369(1-2):105–117. doi:10.1007/s11010-012-1373-0.
  • Schnetz M, Meier JK, Rehwald C, Mertens C, Urbschat A, Tomat E, Akam EA, et al. The Disturbed Iron Phenotype of Tumor Cells and Macrophages in Renal Cell Carcinoma Influences Tumor Growth. Cancers (Basel). 2020;12(3):530. doi:10.3390/cancers12030530.
  • Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276(11):7806–7810. doi:10.1074/jbc.M008922200.
  • Crielaard BJ, Lammers T, Rivella S. Targeting iron metabolism in drug discovery and delivery. Nat Rev Drug Discov. 2017;16(6):400–423. doi:10.1038/nrd.2016.248.
  • Chen Q, Wang L, Ma Y, Wu X, Jin L, Yu F. Increased hepcidin expression in non-small cell lung cancer tissue and serum is associated with clinical stage. Thorac Cancer. 2014;5(1):14–24. doi:10.1111/1759-7714.12046.
  • Pusatcioglu CK, Nemeth E, Fantuzzi G, Llor X, Freels S, Tussing-Humphreys L, et al. Systemic and tumor level iron regulation in men with colorectal cancer: a case control study. Nutr Metab (Lond)). 2014;11:21. doi:10.1186/1743-7075-11-21.
  • Wang F, Liu A, Bai R, Zhang B, Jin Y, Guo W, et al. Hepcidin and iron metabolism in the pathogenesis of prostate cancer. J Buon. 2017;22(5):1328–1332.
  • Zhang S, Chen Y, Guo W, Yuan L, Zhang D, Xu Y, et al. Disordered hepcidin-ferroportin signaling promotes breast cancer growth. Cell Signal. 2014;26(11):2539–2550. doi:10.1016/j.cellsig.2014.07.029.
  • Kamai T, Tomosugi N, Abe H, Arai K, Yoshida K. Increased serum hepcidin-25 level and increased tumor expression of hepcidin mRNA are associated with metastasis of renal cell carcinoma. BMC Cancer. 2009;9(1):270. doi:10.1186/1471-2407-9-270.
  • Traeger L, Ellermann I, Wiethoff H, Ihbe J, Gallitz I, Eveslage M, et al. Serum Hepcidin and GDF-15 levels as prognostic markers in urothelial carcinoma of the upper urinary tract and renal cell carcinoma. BMC Cancer. 2019;19(1):74. doi:10.1186/s12885-019-5278-0.
  • Hara M, Ando M, Tsuchiya K, Nitta K. Serum hepcidin-25 level linked with high mortality in patients with non-Hodgkin lymphoma. Ann Hematol. 2015;94(4):603–608. doi:10.1007/s00277-014-2255-1.
  • Orlandi R, De Bortoli M, Ciniselli CM, Vaghi E, Caccia D, Garrisi V, et al. Hepcidin and ferritin blood level as noninvasive tools for predicting breast cancer. Ann Oncol. 2014;25(2):352–357. doi:10.1093/annonc/mdt490.
  • Pinnix ZK, Miller LD, Wang W, D'Agostino R, Jr., Kute T, Willingham MC, et al. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med. 2010;2(43):43ra56–56.
  • Tesfay L, Clausen KA, Kim JW, Hegde P, Wang X, Miller LD, et al. Hepcidin regulation in prostate and its disruption in prostate cancer. Cancer Res. 2015;75(11):2254–2263. doi:10.1158/0008-5472.CAN-14-2465.
  • Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6(7):655–663.
  • Pandey J, Syed W. 2021. Renal Cancer StatPearls. Treasure Island (FL): StatPearls Publishing; Copyright © 2021, StatPearls Publishing LLC.
  • Nicolae CD, Coman OA, Ene C, Nicolae I, Fulga I. Hepcidin in neoplastic disease. J Med Life. 2013;6(3):355–360.
  • Gregg JL, Turner RM, 2nd, Chang G, Joshi D, Zhan Y, Chen L, Maranchie JK. NADPH oxidase NOX4 supports renal tumorigenesis by promoting the expression and nuclear accumulation of HIF2α. Cancer Res. 2014;74(13):3501–3511. doi:10.1158/0008-5472.CAN-13-2979.
  • Le NT, Richardson DR. The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta. 2002;1603(1):31–46.
  • Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Cancer Genome Atlas Research Network, et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med. 2016;374(2):135–145.
  • Fischer-Fodor E, Miklasova N, Berindan-Neagoe I, Saha B. Iron, inflammation and invasion of cancer cells. Clujul Med. 2015;88(3):272–277. doi:10.15386/cjmed-492.
  • Manz DH, Blanchette NL, Paul BT, Torti FM, Torti SV. Iron and cancer: recent insights. Ann N Y Acad Sci. 2016;1368(1):149–161.
  • Zhao B, Li R, Cheng G, Li Z, Zhang Z, Li J, et al. Role of hepcidin and iron metabolism in the onset of prostate cancer. Oncol Lett. 2018;15(6):9953–9958. doi:10.3892/ol.2018.8544.
  • Luanpitpong S, Talbott SJ, Rojanasakul Y, Nimmannit U, Pongrakhananon V, Wang L, Chanvorachote P. Regulation of lung cancer cell migration and invasion by reactive oxygen species and caveolin-1. J Biol Chem. 2010;285(50):38832–38840. doi:10.1074/jbc.M110.124958.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.